In both cohorts, compared to HCC patients with negative expression of FGF19 or FGFR4, patients with positive expression of FGF19 or FGFR4 had higher recurrence rate and shorter overall survival time (Figure S2D-E). Here, FGF19 is linked to hepatocellular carcinoma.